Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 2,840 Shares

Rapport Therapeutics, Inc. (NASDAQ:RAPP) insider Krishnaswamy Yeleswaram sold 2,840 shares of Rapport Therapeutics stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $30.05, for a total transaction of $85,342.00. Following the sale, the insider directly owned 296,991 shares in the company, valued at $8,924,579.55. This trade represents a 0.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Rapport Therapeutics Price Performance

Shares of NASDAQ:RAPP opened at $27.52 on Tuesday. Rapport Therapeutics, Inc. has a one year low of $6.43 and a one year high of $42.27. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -10.15 and a beta of 1.63. The firm has a 50 day simple moving average of $28.26 and a 200 day simple moving average of $22.31.

Rapport Therapeutics (NASDAQ:RAPP) last posted its earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.06. As a group, analysts expect that Rapport Therapeutics, Inc. will post -3.65 EPS for the current year.

Analyst Upgrades and Downgrades

RAPP has been the topic of a number of research analyst reports. Wells Fargo & Company set a $51.00 price target on Rapport Therapeutics in a report on Friday, December 19th. Wall Street Zen upgraded shares of Rapport Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 14th. BTIG Research reaffirmed a “buy” rating and issued a $47.00 price objective on shares of Rapport Therapeutics in a research note on Monday, December 8th. The Goldman Sachs Group reiterated a “buy” rating on shares of Rapport Therapeutics in a research note on Friday, December 19th. Finally, Citizens Jmp lifted their target price on Rapport Therapeutics from $77.00 to $80.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Rapport Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $48.33.

Hedge Funds Weigh In On Rapport Therapeutics

Institutional investors have recently modified their holdings of the business. Baker BROS. Advisors LP increased its position in shares of Rapport Therapeutics by 181.2% during the third quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock valued at $45,949,000 after acquiring an additional 997,000 shares during the last quarter. Vestal Point Capital LP purchased a new stake in shares of Rapport Therapeutics during the 3rd quarter valued at $28,215,000. Polar Capital Holdings Plc purchased a new stake in shares of Rapport Therapeutics during the 3rd quarter valued at $27,887,000. Capital International Investors raised its stake in shares of Rapport Therapeutics by 30.7% during the 3rd quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock worth $101,055,000 after purchasing an additional 800,000 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Rapport Therapeutics by 265.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 892,258 shares of the company’s stock worth $26,500,000 after buying an additional 648,378 shares during the last quarter.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.